Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of HER2 Chimeric Antigen Receptor Expressing CMV-Specific Cytotoxic T Cells Ins Patients With Glioblastoma Multiforme (HERT-GBM)

NCT01109095 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT01109095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01109095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of HER2 Chimeric Antigen Receptor Expressing CMV-Specific Cytotoxic T Cells Ins Patients With Glioblastoma Multiforme (HERT-GBM)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2010
Completion date
March 7, 2018
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme (gbm)